FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139148124> ?p ?o ?g. }

• W3139148124 endingPage "1532" @default.
• W3139148124 startingPage "1523" @default.
• W3139148124 abstract "Pegloticase is used for the treatment of severe gout, but its use is limited by immunogenicity. This study was undertaken to evaluate whether mycophenolate mofetil (MMF) prolongs the efficacy of pegloticase.Participants were randomized 3:1 to receive 1,000 mg MMF twice daily or placebo for 14 weeks, starting 2 weeks before receiving pegloticase and continuing while receiving intravenous pegloticase 8 mg biweekly for 12 weeks. Participants then received pegloticase alone from week 12 to week 24. The primary end points were the proportion of patients who sustained a serum urate level of ≤6 mg/dl at 12 weeks and the rate of adverse events (AEs). Secondary end points included 24-week durability of serum urate level ≤6 mg/dl. Fisher's exact test and Wilcoxon's 2-sample test were used for analyses, along with Kaplan-Meier estimates and log rank tests.A total of 32 participants received ≥1 dose of pegloticase. Participants were predominantly men (88%), with a mean age of 55.2 years, mean gout duration of 13.4 years, and mean baseline serum urate level of 9.2 mg/dl. At 12 weeks, a serum urate level of ≤6 mg/dl was achieved in 19 (86%) of 22 participants in the MMF arm compared to 4 (40%) of 10 in the placebo arm (P = 0.01). At week 24, the serum urate level was ≤6 mg/dl in 68% of MMF-treated patients versus 30% of placebo-treated patients (P = 0.06), and rates of AEs were similar between groups, with more infusion reactions occurring in the placebo arm (30% versus 0%).Our findings indicate that MMF therapy with pegloticase is well tolerated and shows a clinically meaningful improvement in targeted serum urate level of ≤6 mg/dl at 12 and 24 weeks. This study suggests an innovative approach to pegloticase therapy in gout." @default.
• W3139148124 created "2021-03-29" @default.
• W3139148124 creator A5009710595 @default.
• W3139148124 creator A5010278506 @default.
• W3139148124 creator A5023927761 @default.
• W3139148124 creator A5026981314 @default.
• W3139148124 creator A5032331413 @default.
• W3139148124 creator A5036008316 @default.
• W3139148124 creator A5046382845 @default.
• W3139148124 creator A5053675781 @default.
• W3139148124 creator A5064955501 @default.
• W3139148124 creator A5069421572 @default.
• W3139148124 creator A5073269240 @default.
• W3139148124 creator A5079111754 @default.
• W3139148124 creator A5080554826 @default.
• W3139148124 creator A5082669130 @default.
• W3139148124 creator A5084524552 @default.
• W3139148124 creator A5084810766 @default.
• W3139148124 creator A5089460885 @default.
• W3139148124 date "2021-05-19" @default.
• W3139148124 modified "2023-10-14" @default.
• W3139148124 title "Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial" @default.
• W3139148124 cites W1510116615 @default.
• W3139148124 cites W1561987315 @default.
• W3139148124 cites W1939384019 @default.
• W3139148124 cites W1966639889 @default.
• W3139148124 cites W1984307363 @default.
• W3139148124 cites W1984426896 @default.
• W3139148124 cites W2023159927 @default.
• W3139148124 cites W2024758091 @default.
• W3139148124 cites W2025393559 @default.
• W3139148124 cites W2027100907 @default.
• W3139148124 cites W2034227341 @default.
• W3139148124 cites W2036048816 @default.
• W3139148124 cites W2060403756 @default.
• W3139148124 cites W2061904336 @default.
• W3139148124 cites W2065431406 @default.
• W3139148124 cites W2075863990 @default.
• W3139148124 cites W2094780098 @default.
• W3139148124 cites W2102087425 @default.
• W3139148124 cites W2109218036 @default.
• W3139148124 cites W2110249745 @default.
• W3139148124 cites W2116477373 @default.
• W3139148124 cites W2124669347 @default.
• W3139148124 cites W2126854279 @default.
• W3139148124 cites W2131885572 @default.
• W3139148124 cites W2133287974 @default.
• W3139148124 cites W2134049088 @default.
• W3139148124 cites W2155024437 @default.
• W3139148124 cites W2160388191 @default.
• W3139148124 cites W2172545980 @default.
• W3139148124 cites W2293944201 @default.
• W3139148124 cites W2326355551 @default.
• W3139148124 cites W2329583064 @default.
• W3139148124 cites W2339224595 @default.
• W3139148124 cites W2375209674 @default.
• W3139148124 cites W2403081670 @default.
• W3139148124 cites W2522294631 @default.
• W3139148124 cites W2597733778 @default.
• W3139148124 cites W2755440358 @default.
• W3139148124 cites W2897154311 @default.
• W3139148124 cites W2902068861 @default.
• W3139148124 cites W3023256684 @default.
• W3139148124 cites W3034499962 @default.
• W3139148124 cites W3034847577 @default.
• W3139148124 cites W3044515532 @default.
• W3139148124 cites W4226484168 @default.
• W3139148124 cites W4229537562 @default.
• W3139148124 cites W50336179 @default.
• W3139148124 doi "https://doi.org/10.1002/art.41731" @default.
• W3139148124 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8324571" @default.
• W3139148124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33750034" @default.
• W3139148124 hasPublicationYear "2021" @default.
• W3139148124 type Work @default.
• W3139148124 sameAs 3139148124 @default.
• W3139148124 citedByCount "26" @default.
• W3139148124 countsByYear W31391481242021 @default.
• W3139148124 countsByYear W31391481242022 @default.
• W3139148124 countsByYear W31391481242023 @default.
• W3139148124 crossrefType "journal-article" @default.
• W3139148124 hasAuthorship W3139148124A5009710595 @default.
• W3139148124 hasAuthorship W3139148124A5010278506 @default.
• W3139148124 hasAuthorship W3139148124A5023927761 @default.
• W3139148124 hasAuthorship W3139148124A5026981314 @default.
• W3139148124 hasAuthorship W3139148124A5032331413 @default.
• W3139148124 hasAuthorship W3139148124A5036008316 @default.
• W3139148124 hasAuthorship W3139148124A5046382845 @default.
• W3139148124 hasAuthorship W3139148124A5053675781 @default.
• W3139148124 hasAuthorship W3139148124A5064955501 @default.
• W3139148124 hasAuthorship W3139148124A5069421572 @default.
• W3139148124 hasAuthorship W3139148124A5073269240 @default.
• W3139148124 hasAuthorship W3139148124A5079111754 @default.
• W3139148124 hasAuthorship W3139148124A5080554826 @default.
• W3139148124 hasAuthorship W3139148124A5082669130 @default.
• W3139148124 hasAuthorship W3139148124A5084524552 @default.
• W3139148124 hasAuthorship W3139148124A5084810766 @default.
• W3139148124 hasAuthorship W3139148124A5089460885 @default.
• W3139148124 hasBestOaLocation W31391481242 @default.

• next